Boston Scientific Co. (NYSE:BSX) Stock Holdings Cut by NewSquare Capital LLC

NewSquare Capital LLC cut its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 97.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,763 shares of the medical equipment provider's stock after selling 58,892 shares during the period. NewSquare Capital LLC's holdings in Boston Scientific were worth $102,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Bruce G. Allen Investments LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth $28,000. Motco boosted its holdings in Boston Scientific by 136.3% in the third quarter. Motco now owns 645 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 372 shares during the last quarter. Venturi Wealth Management LLC boosted its holdings in Boston Scientific by 58.0% in the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 215 shares during the last quarter. Asset Dedication LLC raised its position in shares of Boston Scientific by 42.6% in the third quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider's stock worth $41,000 after acquiring an additional 235 shares during the period. Finally, CNB Bank acquired a new position in shares of Boston Scientific in the third quarter worth about $42,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 16,351 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $69.30, for a total value of $1,133,124.30. Following the completion of the sale, the executive vice president now directly owns 50,638 shares of the company's stock, valued at $3,509,213.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Daniel J. Brennan sold 13,662 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the completion of the sale, the chief financial officer now directly owns 271,542 shares of the company's stock, valued at $17,883,756.12. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP John Bradley Sorenson sold 16,351 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the completion of the sale, the executive vice president now directly owns 50,638 shares of the company's stock, valued at $3,509,213.40. The disclosure for this sale can be found here. In the last three months, insiders sold 50,979 shares of company stock valued at $3,418,529. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 5.7 %

Shares of BSX traded up $3.92 during midday trading on Wednesday, reaching $72.91. The stock had a trading volume of 14,206,418 shares, compared to its average volume of 6,540,234. The company has a market cap of $106.97 billion, a price-to-earnings ratio of 68.14, a PEG ratio of 2.38 and a beta of 0.78. The company's fifty day simple moving average is $67.53 and its two-hundred day simple moving average is $60.28. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.04. The business had revenue of $3.73 billion during the quarter, compared to analysts' expectations of $3.59 billion. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. During the same period in the previous year, the company earned $0.45 EPS. Equities research analysts expect that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Raymond James upped their price target on shares of Boston Scientific from $67.00 to $73.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 1st. BTIG Research restated a "buy" rating and set a $64.00 price target on shares of Boston Scientific in a research report on Friday, December 29th. Argus upped their price target on shares of Boston Scientific from $69.00 to $80.00 and gave the stock a "buy" rating in a research report on Wednesday, April 3rd. Royal Bank of Canada increased their price objective on shares of Boston Scientific from $70.00 to $78.00 and gave the company an "outperform" rating in a report on Monday, April 15th. Finally, Wells Fargo & Company increased their price objective on shares of Boston Scientific from $70.00 to $72.00 and gave the company an "overweight" rating in a report on Thursday, February 1st. Two research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $69.00.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.